Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Annual Review of Medicine
|
January 28, 2020
Broadly Neutralizing Antibodies for HIV Prevention
Shelly T Karuna, Lawrence Corey
Vaccine
|
July 18, 2013
Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives
Michele Peake Andrasik, Shelly T Karuna, Michelle Nebergall, et al.
Plos One
|
October 1, 2014
The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier
Maria P Lemos, Javier R Lama, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 19, 2016
Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research
Rona L Siskind, Michele Andrasik, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 26, 2013
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants
Jonathan D Fuchs, Magdalena E Sobieszczyk, Tamra Madenwald, et al.
Vaccine
|
December 3, 2014
Use of placebos in Phase 1 preventive HIV vaccine clinical trials
Yunda Huang, Shelly T Karuna, Holly Janes, et al.
Plos One
|
August 19, 2016
Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection
Javier R Lama, Shelly T Karuna, Shannon P Grant, et al.
Open Forum Infectious Diseases
|
July 22, 2024
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials
Valeria D Cantos, Moni Neradilek, Yunda Huang, et al.
The Journal of Clinical Investigation
|
October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
Pierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 19, 2025
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085
Deborah A Theodore, Moni Neradilek, Kevin Gillespie, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Annual Review of Medicine
|
January 28, 2020
Broadly Neutralizing Antibodies for HIV Prevention
Shelly T Karuna, Lawrence Corey
Vaccine
|
July 18, 2013
Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives
Michele Peake Andrasik, Shelly T Karuna, Michelle Nebergall, et al.
Plos One
|
October 1, 2014
The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier
Maria P Lemos, Javier R Lama, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 19, 2016
Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials Research
Rona L Siskind, Michele Andrasik, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 26, 2013
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants
Jonathan D Fuchs, Magdalena E Sobieszczyk, Tamra Madenwald, et al.
Vaccine
|
December 3, 2014
Use of placebos in Phase 1 preventive HIV vaccine clinical trials
Yunda Huang, Shelly T Karuna, Holly Janes, et al.
Plos One
|
August 19, 2016
Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection
Javier R Lama, Shelly T Karuna, Shannon P Grant, et al.
Open Forum Infectious Diseases
|
July 22, 2024
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials
Valeria D Cantos, Moni Neradilek, Yunda Huang, et al.
The Journal of Clinical Investigation
|
October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
Pierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 19, 2025
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085
Deborah A Theodore, Moni Neradilek, Kevin Gillespie, et al.
Page
of 3